Skip to content

Ovagen

Khavinson bioregulator

Also: EDL · Glu-Asp-Leu · H-Glu-Asp-Leu-OH · T-35 · peptide complex AC-3 · Ovagen Liver · Оваген

CautionGutMetabolic & weightInjection / Oral

Khavinson 'liver' tripeptide EDL; its liver data sit in a patent, its published work in rat kidneys.

Safety tier
Caution
strict bar
Positive
58%
of 4 reports
Per month
≈ €50–90≈ $56–100
estimate
Rank
#4
of 86 research peptides

At a glance

Onset
Not felt acutely; the reports judge it over a course, and one X user noticed less bloating within days.
Lasts
Taken as 1-month capsule courses repeated every 3-6 months, or 10-40 day injection courses from a 20 mg vial; no report says how long any benefit lasts.
Access
Grey market
Best effects
Claimed: normalised ALT and bilirubin in chronic hepatitis (developers' patent only) · feeling better and more energetic during a course (one user, while quitting alcohol) · less bloating after heavy eating (one X user)
Downsides
No effect for some (one X user felt nothing) · impossible to separate from lifestyle changes made at the same time · grey-market vials are dosed 10-50x higher than the capsules with no published rationale
Typical use
Grey-market vials: 200 mcg to 1 mg subq a day until a 20 mg vial is used; the patent's injections ranged from 1 mcg to 5 mg IM daily for 10 days. Capsules: 1-2 capsules (0.1-0.2 mg) twice a day with meals for 1 month, repeated after 3-6 months (manufacturer).
Stacked with
Stacked with
Livagen: The usual follow-on for liver courses; the one Reddit user moved from Ovagen to Livagen. · Vesugen, Pinealon and other bioregulators: X users run it in a set of four (Ovagen, Endoluten, Vesugen, Vladonix), and Khavinson material pairs it with Cartalax in a rotating 30-day protocol. · TUDCA or milk thistle: Suggested alongside it for liver support by people cycling steroids; no reports of the combination.

Safety

Watch
In the developers' own cell work EDL raised proliferation and lowered the p53, p16 and p21 ageing and cell-cycle brakes in kidney cells, and the patent reports more dividing liver cells after partial hepatectomy; a single-group signal of unknown meaning · Grey-market injectable vials: purity, sterility and identity unverified
Tier by safety barStrict CautionBalanced CautionEvidence only Clean
  • Seen harm0 of 3
  • Mechanism1 of 3
  • Data gap3 of 3
  • Silent harm1 of 3
  • Product3 of 3
Never if
Pregnancy or breastfeeding (no human reproductive data) · Hepatitis, cirrhosis or alcoholic liver disease used in place of medical treatment and monitoring
Why each score
Seen harm 0/3
No serious adverse event appears in any source or first-hand account; the developers' patent reports none in 19 injected hepatitis patients. The zero reflects almost no documented human exposure (an unpublished patent example and four first-hand posts), not reassurance. Patent WO 2007/139430: Glu-Asp-Leu, toxicity and clinical examples
Mechanism 1/3
No named pathway to serious harm. The only signals are single-group: in kidney-cell cultures EDL raised proliferation and lowered p53, p16 and p21, and the patent reports more dividing liver cells after partial hepatectomy in rats. Unreplicated and tied to repair models, so speculative; the same group's rat kidney studies and 6-month guinea-pig toxicity found no harm. Khavinson et al. 2014: Tripeptides slow down aging process in renal cell culture (PubMed 25946838)Patent WO 2007/139430: partial hepatectomy and toxicity examples
Data gap 3/3
Registered nowhere as a drug, and no peer-reviewed human data for EDL: the only human figures are a 34-patient chronic-hepatitis example in the developers' patent. Published work is rat kidney studies and kidney-cell cultures, none in liver or gut. Patent WO 2007/139430 (Glu-Asp-Leu)Zamorskii et al. 2017: EDL in rat acute kidney injury (PubMed 28744634)
Silent harm 1/3
With no credible mechanism, rated on the most plausible harms: injection-site or allergic reactions to grey-market vials and stomach upset from capsules, which are noticed at once and stop with the course.
Product 3/3
The Reddit report and grey-market listings (Swiss Chems and others, 20 mg vials) are injectable powder of unverified purity and sterility; the Khavinson-line capsules (0.1 mg per capsule, sold as a supplement) are the lower-risk alternative some X users take. r/Ovagen: Sub-Q Ovagen protocol (20 mg vial, injected)Mendias & Awan 2026 preprint: 6,441 grey-market peptide samples, 42-71% failed quality criteria, 15% had endotoxin

User reports

All 4 reports
Users report
Too few reports to judge, and the few are vague. On Reddit only one person said how it went: he injected a 20 mg vial over a course while quitting alcohol, felt much better and recommends it, but says he cannot separate the peptide from stopping drinking and did not check his liver enzymes. Three posts on X: one user felt no improvement from Ovagen or Pinealon, one credits it for a junk-food binge without the usual bloating and called it the most noticeable of four bioregulators, and one says it helped his and his wife's liver health without giving numbers. Nobody reports a measured change in ALT, AST or bilirubin. Felt nothing: 1 of 4 first-hand reports; too few to judge.
Positive 3Nothing 1
  • @izem000

    I'm convinced Ovagen (bioregulator) is the reason I was able to binge for 4 days junk food, insane amount of calories and not feel bloated

    • 15 likes
    Positive
  • @Oleg_Bowtied

    Ovagen helped mine and wife’s liver health

    • 13 likes
    Positive
  • @AdamFromParis75

    I tried ovagen and pinealon from the same brand, i felt ZERO improvement, has to be said.

    • 3 likes
    Nothing

Studies

Evidence
Animal only — The liver claim rests on the developers' 2006 patent (rat partial hepatectomy and cirrhosis, guinea-pig toxicity, and 34 chronic-hepatitis patients given injections), never published in a journal. Everything peer-reviewed on EDL is rat kidney work by a Ukrainian team co-authoring with the Khavinson institute, plus kidney-cell cultures; the group's own 2021 review of liver peptides covers Livagen (KEDA), not EDL. No published gut study was found.
Caveat
Evidence that Ovagen does anything for the liver is a patent, not a paper: the peer-reviewed EDL work is all in rat kidneys and kidney cells, and the gut claim has no study at all. EDL is a tiny acidic tripeptide with no named harm pathway beyond a single-group proliferation signal, so the verdict reflects thin data rather than a credible risk, but there are no published human safety data, and injected grey-market vials (at up to 10 times the capsule dose daily) are a different exposure from the capsules.
3 more studies and 4 sources

Sources

Similar peptides

Research notes, not medical advice. Updated . Also as Markdown.

Sequence

The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.

Report grades

Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.

GlowingPositiveMixedNothingNegativeBad reaction

% positive

The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.

Researcher estimate

No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.

Safety tier

Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.

Safety bar

The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.

Seen harm

Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.

Mechanism

A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.

Data gap

How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.

Silent harm

Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.

Product

The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.

Evidence

The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.

Access

How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.

Price per month

Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. The shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.

Dose users report

The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.

Shop trust

Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.

Best value

Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.

Testing

Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.

Added peptide

Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.